Boston Scientific touts spinal cord stim pain-relief trial

This study provides data on people who have suffered with chronic pain for years and who pose some of the biggest challenges in the long-term use of SCS. The results demonstrated that giving patients the choice to use sub-perception or paresthesia-based therapy provides superior patient outcomes and affirms that SCS is a clinically valuable treatment option.” The trial showed that if patients are able to choose the type of therapy that brings them the most effective pain relief, the number of people whose pain was effectively controlled by SCS jumped by 62%. More than half of the patients in one of the study’s cohorts preferred having the option of both sub-perception and paresthesia-based therapy. Participants whose pain was managed by paresthesia-based therapy experienced an average reduction in baseline pain scores from 7.2 to 2.5, Boston Scientific reported. After one year, people who preferred sub-perception therapy saw their pain scores decrease on average from 7.1 to 3.8. “This rigorous, carefully conducted trial underscores the importance of providing patients with multiple therapeutic options for the relief of chronic pain in one SCS system that can help address their complex needs,” Maulik Nanavaty, president & SVP of Boston Scientific’s neuromodulation business, added. “We are dedicated to improving the lives of patients with industry-leading neuromodulation technology designed for long-lasting relief.” The post Boston ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neuromodulation/Neurostimulation Pain Management Spinal Wall Street Beat Boston Scientific Source Type: news